Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127304 · ClinicalTrials.gov registry record
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 11,316
- Enrollment target
NCT05127304 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 11,316 participants.
The verdict
NCT05127304 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 11,316 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Interventions
- DEVICE Trelegy Ellipta
- DEVICE Stiolto Respimat
- DRUG Furoate/Umeclidinium/Vilanterol
- DRUG Tiotropium Bromide/Olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,316 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2022-02-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05127304
The ClinicalTrials.gov registry entry for NCT05127304 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11,316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trelegy Ellipta is the first listed.
NCT05127304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05127304 about?
NCT05127304 is a clinical study titled "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol". The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)...
What is the current status of trial NCT05127304?
This trial is currently completed. The enrollment target is 11,316 participants. The study started on 2021-02-26. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT05127304?
The interventions under investigation include: Trelegy Ellipta (DEVICE), Stiolto Respimat (DEVICE), Furoate/Umeclidinium/Vilanterol (DRUG), Tiotropium Bromide/Olodaterol (DRUG).
Who is sponsoring clinical trial NCT05127304?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.